Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.2721 USD
−66.95 M USD
28.70 M USD
222.15 M
About Vaxart, Inc.
Sector
Industry
CEO
Steven Lo
Website
Headquarters
South San Francisco
Founded
2004
FIGI
BBG000DR2253
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of VXRT is 0.4407 USD — it has increased by 8.84% in the past 24 hours. Watch Vaxart, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Vaxart, Inc. stocks are traded under the ticker VXRT.
VXRT stock has risen by 31.99% compared to the previous week, the month change is a −26.55% fall, over the last year Vaxart, Inc. has showed a −37.93% decrease.
We've gathered analysts' opinions on Vaxart, Inc. future price: according to them, VXRT price has a max estimate of 8.00 USD and a min estimate of 2.00 USD. Watch VXRT chart and read a more detailed Vaxart, Inc. stock forecast: see what analysts think of Vaxart, Inc. and suggest that you do with its stocks.
VXRT reached its all-time high on May 5, 2004 with the price of 77,987.9516 USD, and its all-time low was 0.2543 USD and was reached on Sep 25, 2019. View more price dynamics on VXRT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
VXRT stock is 14.97% volatile and has beta coefficient of 1.79. Track Vaxart, Inc. stock price on the chart and check out the list of the most volatile stocks — is Vaxart, Inc. there?
Today Vaxart, Inc. has the market capitalization of 100.62 M, it has decreased by −9.58% over the last week.
Yes, you can track Vaxart, Inc. financials in yearly and quarterly reports right on TradingView.
Vaxart, Inc. is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
VXRT earnings for the last quarter are −0.07 USD per share, whereas the estimation was −0.10 USD resulting in a 27.59% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Vaxart, Inc. earnings.
Vaxart, Inc. revenue for the last quarter amounts to 20.88 M USD, despite the estimated figure of 2.85 M USD. In the next quarter, revenue is expected to reach 2.03 M USD.
VXRT net income for the last quarter is −15.59 M USD, while the quarter before that showed −11.98 M USD of net income which accounts for −30.09% change. Track more Vaxart, Inc. financial stats to get the full picture.
No, VXRT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 20, 2025, the company has 115 employees. See our rating of the largest employees — is Vaxart, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vaxart, Inc. EBITDA is −52.76 M USD, and current EBITDA margin is −215.66%. See more stats in Vaxart, Inc. financial statements.
Like other stocks, VXRT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vaxart, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vaxart, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vaxart, Inc. stock shows the sell signal. See more of Vaxart, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.